Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GLPG 
Galapagos NV ADR (GLPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: GLPG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.5
1 Year Target Price $25.5
| 0 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.72% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.28B USD | Price to earnings Ratio - | 1Y Target Price 25.5 |
Price to earnings Ratio - | 1Y Target Price 25.5 | ||
Volume (30-day avg) 6 | Beta 0.06 | 52 Weeks Range 22.36 - 37.78 | Updated Date 10/18/2025 |
52 Weeks Range 22.36 - 37.78 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -103.14% | Operating Margin (TTM) -87.35% |
Management Effectiveness
Return on Assets (TTM) -5.11% | Return on Equity (TTM) -10.39% |
Valuation
Trailing PE - | Forward PE 344.83 | Enterprise Value -1266917567 | Price to Sales(TTM) 8.29 |
Enterprise Value -1266917567 | Price to Sales(TTM) 8.29 | ||
Enterprise Value to Revenue 1.18 | Enterprise Value to EBITDA -31.5 | Shares Outstanding 65897071 | Shares Floating 35823625 |
Shares Outstanding 65897071 | Shares Floating 35823625 | ||
Percent Insiders 25.35 | Percent Institutions 22.97 |
Upturn AI SWOT
Galapagos NV ADR
Company Overview
History and Background
Galapagos NV was founded in 1999 in Mechelen, Belgium, as a drug discovery and development company focused on novel modes-of-action. Significant milestones include partnerships with major pharmaceutical companies, the development of Filgotinib, and becoming a fully integrated biopharmaceutical company.
Core Business Areas
- Research and Development: Focuses on discovering and developing innovative therapies for diseases with high unmet medical needs. Targets areas like inflammation, fibrosis, and other disease areas.
- Commercialization: Commercializes approved therapies like Jyseleca (filgotinib) in certain markets, particularly in Europe.
- Partnerships: Collaborates with pharmaceutical companies to advance drug development and commercialization efforts.
Leadership and Structure
The leadership team includes key executives responsible for R&D, commercial operations, and corporate strategy. The organizational structure comprises research, development, commercial, and support functions.
Top Products and Market Share
Key Offerings
- Jyseleca (filgotinib): A selective JAK1 inhibitor approved for rheumatoid arthritis and ulcerative colitis in Europe and Japan. The market share is still developing. Competitors include AbbVie's Rinvoq and Pfizer's Xeljanz. Revenue for 2023 was u20ac98.9 million.
- Toledo Program: A novel program targeting inflammation and fibrosis, currently in clinical development. This program does not have market share yet. Competitors include companies developing similar drugs in the same therapeutic areas, such as Boehringer Ingelheim in fibrosis.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. It is currently experiencing growth driven by innovation in therapies for unmet medical needs.
Positioning
Galapagos is positioned as an innovative biopharmaceutical company focusing on novel modes-of-action. Its competitive advantage lies in its research and development capabilities and strategic partnerships.
Total Addressable Market (TAM)
The TAM for Galapagos's therapeutic areas is estimated to be in the tens of billions of dollars globally. Galapagos aims to capture a significant share through successful drug development and commercialization.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Innovative pipeline
- Strategic partnerships
- Commercial presence in Europe and Japan
Weaknesses
- Reliance on Filgotinib for revenue
- High R&D expenses
- Limited commercial presence in the US
- Pipeline risk associated with drug development
Opportunities
- Expansion of Filgotinib's indications
- Development of new therapies
- Strategic acquisitions
- Partnerships for US commercialization
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expiration
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- PFE
- LLY
Competitive Landscape
Galapagos faces intense competition from larger, more established pharmaceutical companies. Its advantages include its innovative pipeline and strategic partnerships. Disadvantages include limited commercial infrastructure compared to larger competitors.
Major Acquisitions
CellPoint Technologies
- Year: 2022
- Acquisition Price (USD millions): 13
- Strategic Rationale: Expanded access to innovative technologies focused on cell therapy research and development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by R&D success and commercialization of Jyseleca. Revenue has fluctuated based on partnership deals and milestone payments.
Future Projections: Future growth is expected to be driven by the success of the Toledo program and potential expansion of Jyseleca's indications. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include strategic collaborations, pipeline advancement, and efforts to optimize commercial operations.
Summary
Galapagos is a biopharmaceutical company with promising R&D capabilities, but it faces challenges in profitability and competition. The success of its pipeline and commercialization strategies will determine its future growth. The company must look out for regulatory hurdles and competition from more established pharmaceutical companies. Recent acquisitions show positive strategic alignment with growing the pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (Annual Reports, SEC Filings)
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galapagos NV ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2005-05-06 | CEO & Executive Director Mr. Henry Gosebruch | ||
Sector Healthcare | Industry Biotechnology | Full time employees 558 | Website https://www.glpg.com |
Full time employees 558 | Website https://www.glpg.com | ||
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.